JP2018510220A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018510220A5 JP2018510220A5 JP2018500282A JP2018500282A JP2018510220A5 JP 2018510220 A5 JP2018510220 A5 JP 2018510220A5 JP 2018500282 A JP2018500282 A JP 2018500282A JP 2018500282 A JP2018500282 A JP 2018500282A JP 2018510220 A5 JP2018510220 A5 JP 2018510220A5
- Authority
- JP
- Japan
- Prior art keywords
- silybin
- composition
- isosilybin
- range
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 42
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 32
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 claims 28
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 claims 28
- FDQAOULAVFHKBX-UHFFFAOYSA-N Isosilybin A Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC(=CC=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 FDQAOULAVFHKBX-UHFFFAOYSA-N 0.000 claims 21
- 229920000858 Cyclodextrin Polymers 0.000 claims 16
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 16
- 125000004964 sulfoalkyl group Chemical group 0.000 claims 16
- FDQAOULAVFHKBX-KMRPREKFSA-N (+)-Isosilybin A Natural products C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC(=CC=C3O2)[C@@H]2[C@@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 FDQAOULAVFHKBX-KMRPREKFSA-N 0.000 claims 12
- FDQAOULAVFHKBX-HKTJVKLFSA-N (2r,3r)-3,5,7-trihydroxy-2-[(2r,3r)-2-(4-hydroxy-3-methoxyphenyl)-3-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3-dihydrochromen-4-one Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC(=CC=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 FDQAOULAVFHKBX-HKTJVKLFSA-N 0.000 claims 12
- SEBFKMXJBCUCAI-WAABAYLZSA-N (2r,3r)-3,5,7-trihydroxy-2-[(2s,3s)-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3-dihydrochromen-4-one Chemical compound C1=C(O)C(OC)=CC([C@H]2[C@@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-WAABAYLZSA-N 0.000 claims 10
- CXQWRCVTCMQVQX-LSDHHAIUSA-N (+)-taxifolin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC=C(O)C(O)=C1 CXQWRCVTCMQVQX-LSDHHAIUSA-N 0.000 claims 8
- FDQAOULAVFHKBX-WAABAYLZSA-N (2r,3r)-3,5,7-trihydroxy-2-[(2s,3s)-2-(4-hydroxy-3-methoxyphenyl)-3-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3-dihydrochromen-4-one Chemical compound C1=C(O)C(OC)=CC([C@H]2[C@@H](OC3=CC(=CC=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 FDQAOULAVFHKBX-WAABAYLZSA-N 0.000 claims 8
- FDQAOULAVFHKBX-MNPDLOSFSA-N Isosilybin B Natural products C1=C(O)C(OC)=CC([C@@H]2[C@@H](OC3=CC(=CC=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 FDQAOULAVFHKBX-MNPDLOSFSA-N 0.000 claims 8
- 229960004245 silymarin Drugs 0.000 claims 8
- 235000017700 silymarin Nutrition 0.000 claims 8
- 229950004878 silicristin Drugs 0.000 claims 7
- BMLIIPOXVWESJG-LMBCONBSSA-N silychristin Chemical compound C1=C(O)C(OC)=CC([C@H]2[C@@H](C3=C(C(=CC(=C3)[C@@H]3[C@H](C(=O)C4=C(O)C=C(O)C=C4O3)O)O)O2)CO)=C1 BMLIIPOXVWESJG-LMBCONBSSA-N 0.000 claims 7
- BMLIIPOXVWESJG-UHFFFAOYSA-N silychristin A Natural products C1=C(O)C(OC)=CC(C2C(C3=C(C(=CC(=C3)C3C(C(=O)C4=C(O)C=C(O)C=C4O3)O)O)O2)CO)=C1 BMLIIPOXVWESJG-UHFFFAOYSA-N 0.000 claims 7
- CYGIJEJDYJOUAN-UHFFFAOYSA-N Isosilychristin Natural products C1=C(O)C(OC)=CC(C2C3C=C(C4C(C3=O)(O)OCC42)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 CYGIJEJDYJOUAN-UHFFFAOYSA-N 0.000 claims 5
- 229950004304 silidianin Drugs 0.000 claims 5
- CYGIJEJDYJOUAN-JSGXPVSSSA-N silydianin Chemical compound C1=C(O)C(OC)=CC([C@H]2[C@H]3C=C([C@@H]4[C@@](C3=O)(O)OC[C@@H]42)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 CYGIJEJDYJOUAN-JSGXPVSSSA-N 0.000 claims 5
- 210000003491 skin Anatomy 0.000 claims 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 4
- KQNGHARGJDXHKF-UHFFFAOYSA-N dihydrotamarixetin Natural products C1=C(O)C(OC)=CC=C1C1C(O)C(=O)C2=C(O)C=C(O)C=C2O1 KQNGHARGJDXHKF-UHFFFAOYSA-N 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- SEBFKMXJBCUCAI-KMRPREKFSA-N (2r,3s)-3,5,7-trihydroxy-2-[(2r,3r)-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3-dihydrochromen-4-one Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-KMRPREKFSA-N 0.000 claims 3
- SEBFKMXJBCUCAI-WQDFSMHNSA-N (2r,3s)-3,5,7-trihydroxy-2-[(2s,3s)-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3-dihydrochromen-4-one Chemical compound C1=C(O)C(OC)=CC([C@H]2[C@@H](OC3=CC=C(C=C3O2)[C@@H]2[C@@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-WQDFSMHNSA-N 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 230000001965 increasing effect Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 2
- 102000004889 Interleukin-6 Human genes 0.000 claims 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 2
- 102000004890 Interleukin-8 Human genes 0.000 claims 2
- 108090001007 Interleukin-8 Proteins 0.000 claims 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims 2
- 150000001768 cations Chemical class 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 229940100601 interleukin-6 Drugs 0.000 claims 2
- 229940096397 interleukin-8 Drugs 0.000 claims 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
- 229960005323 phenoxyethanol Drugs 0.000 claims 2
- 102100027522 Baculoviral IAP repeat-containing protein 7 Human genes 0.000 claims 1
- 101710177963 Baculoviral IAP repeat-containing protein 7 Proteins 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 claims 1
- 102000016359 Fibronectins Human genes 0.000 claims 1
- 108010067306 Fibronectins Proteins 0.000 claims 1
- 206010019668 Hepatic fibrosis Diseases 0.000 claims 1
- 206010056328 Hepatic ischaemia Diseases 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 claims 1
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 206010067125 Liver injury Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 108010050808 Procollagen Proteins 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 241001303601 Rosacea Species 0.000 claims 1
- VLGROHBNWZUINI-UHFFFAOYSA-N Silybin Natural products COc1cc(ccc1O)C2OC3C=C(C=CC3OC2CO)C4Oc5cc(O)cc(O)c5C(=O)C4O VLGROHBNWZUINI-UHFFFAOYSA-N 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 claims 1
- 208000002353 alcoholic hepatitis Diseases 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 235000006708 antioxidants Nutrition 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 210000004207 dermis Anatomy 0.000 claims 1
- 210000002615 epidermis Anatomy 0.000 claims 1
- 230000001815 facial effect Effects 0.000 claims 1
- 231100000234 hepatic damage Toxicity 0.000 claims 1
- 230000002440 hepatic effect Effects 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 229960003130 interferon gamma Drugs 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 230000008818 liver damage Effects 0.000 claims 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 1
- 230000036542 oxidative stress Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000003716 rejuvenation Effects 0.000 claims 1
- 201000004700 rosacea Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000036573 scar formation Effects 0.000 claims 1
- -1 silichristin Chemical compound 0.000 claims 1
- 229940043175 silybin Drugs 0.000 claims 1
- 235000014899 silybin Nutrition 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021105815A JP7239640B2 (ja) | 2015-03-19 | 2021-06-25 | シリマリンおよびスルホアルキルエーテルシクロデキストリンを含有する組成物ならびにそれを使用する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562135625P | 2015-03-19 | 2015-03-19 | |
| US62/135,625 | 2015-03-19 | ||
| PCT/US2016/023309 WO2016149685A1 (en) | 2015-03-19 | 2016-03-18 | Compositions containing silymarin and sulfoalkyl ether cyclodextrin and methods of using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021105815A Division JP7239640B2 (ja) | 2015-03-19 | 2021-06-25 | シリマリンおよびスルホアルキルエーテルシクロデキストリンを含有する組成物ならびにそれを使用する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018510220A JP2018510220A (ja) | 2018-04-12 |
| JP2018510220A5 true JP2018510220A5 (https=) | 2019-05-09 |
| JP6971963B2 JP6971963B2 (ja) | 2021-11-24 |
Family
ID=56919564
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018500282A Active JP6971963B2 (ja) | 2015-03-19 | 2016-03-18 | シリマリンおよびスルホアルキルエーテルシクロデキストリンを含有する組成物ならびにそれを使用する方法 |
| JP2021105815A Active JP7239640B2 (ja) | 2015-03-19 | 2021-06-25 | シリマリンおよびスルホアルキルエーテルシクロデキストリンを含有する組成物ならびにそれを使用する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021105815A Active JP7239640B2 (ja) | 2015-03-19 | 2021-06-25 | シリマリンおよびスルホアルキルエーテルシクロデキストリンを含有する組成物ならびにそれを使用する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US10702568B2 (https=) |
| EP (3) | EP3939582B1 (https=) |
| JP (2) | JP6971963B2 (https=) |
| CN (1) | CN108348560A (https=) |
| CA (1) | CA2980170A1 (https=) |
| ES (1) | ES3029362T3 (https=) |
| HR (1) | HRP20211303T1 (https=) |
| MX (2) | MX384365B (https=) |
| WO (1) | WO2016149685A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108348560A (zh) | 2015-03-19 | 2018-07-31 | 锡德克斯药物公司 | 包含水飞蓟素和磺烃基醚环糊精的组合物及其使用方法 |
| US20190060212A1 (en) * | 2017-08-23 | 2019-02-28 | Roman Aleksandrovich | Cosmetic Cream with Anti-Oxidant Activity |
| RU2645092C1 (ru) * | 2017-10-05 | 2018-02-15 | Сергей Александрович Староверов | Гепатопротекторная инъекционная фармацевтическая композиция на основе силимарина и наночастиц селена |
| KR102050286B1 (ko) * | 2018-02-08 | 2019-12-02 | 전북대학교산학협력단 | 건강기능식품 및 이의 제조방법 |
| US12150949B2 (en) | 2018-07-30 | 2024-11-26 | Curology, Inc. | Compositions and methods of treating acne and photoaging |
| KR102143405B1 (ko) * | 2018-11-16 | 2020-08-11 | 한국화학연구원 | 리그난 포접물 및 이의 제조 방법 |
| CN115701985A (zh) * | 2020-04-16 | 2023-02-14 | 伊万涅姆医疗保健股份有限公司 | 具有硫胺素的二氢槲皮素制剂 |
| CN113197877B (zh) * | 2021-04-02 | 2022-11-11 | 海南普利制药股份有限公司 | 包含水飞蓟素的药物组合物 |
| CN117915910A (zh) * | 2021-09-21 | 2024-04-19 | 株式会社漫丹 | 免疫相关细胞的初级纤毛的抑制剂及其应用 |
| KR102582322B1 (ko) * | 2023-03-27 | 2023-09-26 | (주)이너네이쳐 | 밀크씨슬 추출물이 포함되는 간 보호용 건강기능식품 조성물 및 이의 제조방법 |
| CN117547515B (zh) * | 2023-11-20 | 2024-04-16 | 黑龙江中医药大学 | 一种含有平贝母的口腔片剂及其制备方法 |
| CN118178391B (zh) * | 2024-05-14 | 2024-07-16 | 深圳北京大学香港科技大学医学中心 | 异水飞蓟宾a在缓解玫瑰痤疮中的应用 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3426011A (en) | 1967-02-13 | 1969-02-04 | Corn Products Co | Cyclodextrins with anionic properties |
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| US4847071A (en) | 1987-10-22 | 1989-07-11 | The Procter & Gamble Company | Photoprotection compositions comprising tocopherol sorbate and an anti-inflammatory agent |
| GB8909095D0 (en) | 1989-04-21 | 1989-06-07 | Allied Colloids Ltd | Thickened aqueous compositions |
| US5087445A (en) | 1989-09-08 | 1992-02-11 | Richardson-Vicks, Inc. | Photoprotection compositions having reduced dermal irritation |
| IT1241673B (it) | 1989-10-09 | 1994-01-27 | Istituto Biochimico Italiano | Complessi di inclusione di silibinina con ciclodestrina, loro preparazione e composizioni farmaceutiche che li contengono. |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| DE69127256T2 (de) | 1990-05-21 | 1998-02-12 | Toppan Printing Co Ltd | Cyclodextrinderivat |
| DE4101122A1 (de) | 1991-01-16 | 1992-07-23 | Betrix Cosmetic Gmbh & Co | Kosmetisches oder pharmazeutisches mittel |
| IT1253431B (it) * | 1991-12-02 | 1995-08-08 | Valetudo S R L | Preparati farmaceutici per uso topico destinati al trattamento della psoriasi e della dermatite atopica |
| DE4401902C2 (de) | 1994-01-24 | 2000-02-03 | Madaus Ag | Verwendung von Flavolignanen als Adjuvans in der Tumortherapie |
| US5874418A (en) | 1997-05-05 | 1999-02-23 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use |
| ES2257795T3 (es) | 1997-07-01 | 2006-08-01 | Pfizer Products Inc. | Procedimiento para producir una ciclodextrina. |
| US5997887A (en) | 1997-11-10 | 1999-12-07 | The Procter & Gamble Company | Skin care compositions and method of improving skin appearance |
| US5972993A (en) | 1998-03-20 | 1999-10-26 | Avon Products, Inc. | Composition and method for treating rosacea and sensitive skin with free radical scavengers |
| US6187822B1 (en) | 1999-06-11 | 2001-02-13 | University Of Medicine & Dentistry Of Nj | Wound treatment through inhibition of adenosine diphosphate ribosyl transferase |
| TWI242015B (en) | 1999-11-29 | 2005-10-21 | Akzo Nobel Nv | 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block |
| KR20030041577A (ko) | 2001-11-20 | 2003-05-27 | 디디에스텍주식회사 | 난용성 약물과 치환된 시클로덱스트린을 함유하는고체분산체 및 이를 함유하는 약제학적 조성물 |
| CN1164269C (zh) | 2002-08-16 | 2004-09-01 | 广州瑞济生物技术有限公司 | 含环糊精或其衍生物的水飞蓟素注射液 |
| CN1424112A (zh) * | 2002-12-17 | 2003-06-18 | 上海医药工业研究院 | 难溶性药物的水溶性包合物及其制备方法 |
| JP4689468B2 (ja) | 2003-07-10 | 2011-05-25 | 協和発酵バイオ株式会社 | 錠剤およびその製造方法 |
| WO2005042584A2 (en) | 2003-10-31 | 2005-05-12 | The University Of Kansas | Sulfoalkyl ether-alkyl ether cyclodextrin derivatives |
| CN1679542A (zh) | 2004-04-06 | 2005-10-12 | 山东绿叶天然药物研究开发有限公司 | 水飞蓟宾盐冻干粉针及其制备方法 |
| MXPA06012777A (es) * | 2004-05-06 | 2007-02-14 | Cydex Inc | Formulaciones de sabor enmascarado que contienen sertralina y eter sulfoalquilico-ciclodextrina. |
| CN1593591A (zh) * | 2004-07-13 | 2005-03-16 | 邢为藩 | 一种水飞蓟提取物环糊精包合物的制备方法及其药物制剂 |
| FR2881953A1 (fr) * | 2005-02-11 | 2006-08-18 | Greenpharma Sa Sa | Utilisation de derives de la taxifoline comme agents pigmentants et protecteurs de la peau ou des cheveux |
| JP4033877B2 (ja) | 2005-09-29 | 2008-01-16 | 株式会社ファンケル | Ｉ型コラーゲン産生促進用組成物 |
| DK1945228T4 (da) | 2005-10-26 | 2015-01-12 | Cydex Pharmaceuticals Inc | Sulfoalkyl-ether-cyclodextrin-sammensætninger og fremgangsmåder til fremstilling deraf |
| JP5351414B2 (ja) | 2006-12-25 | 2013-11-27 | 株式会社ファンケル | シリビン含有化粧料組成物 |
| US7993630B2 (en) * | 2007-02-17 | 2011-08-09 | Bioderm Research | Protection of skin from UV and peroxide |
| WO2009018326A2 (en) * | 2007-07-31 | 2009-02-05 | Limerick Biopharma, Inc. | Soluble pyrone analogs methods and compositions |
| CZ300846B6 (cs) | 2008-06-26 | 2009-08-26 | Agra Group, A. S. | Vodorozpustný prípravek na bázi flavanonol lignanu a zpusob jeho prípravy |
| KR20100052262A (ko) | 2008-11-10 | 2010-05-19 | (주)아모레퍼시픽 | 난용성 약물의 나노입자를 포함하는 분말의 제조방법, 그에의해 제조된 분말 및 이를 포함하는 약학적 조성물 |
| KR101128450B1 (ko) | 2008-12-11 | 2012-03-28 | (주)바이오제닉스 | 안정화제로서 β-싸이클로덱스트린 유도체를 포함하는 조성물 |
| JP5841048B2 (ja) | 2009-05-14 | 2016-01-06 | エウロメッド・エセ・ア | ウイルス性肝炎の治療のための非晶質シリビニン |
| WO2011044638A1 (en) | 2009-10-15 | 2011-04-21 | Howard J. Smith & Associates Pty Ltd | Method of treatment of liver disease |
| CN101810660B (zh) | 2009-12-31 | 2011-06-08 | 江苏健佳药业有限公司 | 水溶性水飞蓟素及其制备方法 |
| CN102106819A (zh) | 2010-12-29 | 2011-06-29 | 中国药科大学 | 药物-环糊精包合物自微乳组合物的制备方法及应用 |
| US8877259B2 (en) | 2012-02-09 | 2014-11-04 | Mary Kay Inc. | Cosmetic formulation |
| CN105816422B (zh) * | 2015-01-05 | 2020-08-14 | 天士力医药集团股份有限公司 | 一种水飞蓟宾注射剂及其制备方法 |
| CN108348560A (zh) | 2015-03-19 | 2018-07-31 | 锡德克斯药物公司 | 包含水飞蓟素和磺烃基醚环糊精的组合物及其使用方法 |
-
2016
- 2016-03-18 CN CN201680028003.3A patent/CN108348560A/zh active Pending
- 2016-03-18 EP EP21175318.1A patent/EP3939582B1/en active Active
- 2016-03-18 CA CA2980170A patent/CA2980170A1/en active Pending
- 2016-03-18 JP JP2018500282A patent/JP6971963B2/ja active Active
- 2016-03-18 US US15/559,005 patent/US10702568B2/en active Active
- 2016-03-18 MX MX2017011966A patent/MX384365B/es unknown
- 2016-03-18 EP EP25173017.2A patent/EP4620534A3/en active Pending
- 2016-03-18 EP EP16765878.0A patent/EP3270941B1/en active Active
- 2016-03-18 HR HRP20211303TT patent/HRP20211303T1/hr unknown
- 2016-03-18 WO PCT/US2016/023309 patent/WO2016149685A1/en not_active Ceased
- 2016-03-18 ES ES21175318T patent/ES3029362T3/es active Active
-
2017
- 2017-09-18 MX MX2021008312A patent/MX2021008312A/es unknown
-
2020
- 2020-07-02 US US16/920,127 patent/US11382944B2/en active Active
-
2021
- 2021-06-25 JP JP2021105815A patent/JP7239640B2/ja active Active
-
2022
- 2022-06-29 US US17/853,761 patent/US12390506B2/en active Active
-
2025
- 2025-08-12 US US19/298,014 patent/US20260091073A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018510220A5 (https=) | ||
| RU2013141845A (ru) | Фармацевтическая композиция в виде крема, содержащая оксиметазолин, для лечения симптомов розацеа | |
| ZA202006137B (en) | Substituted imidazolidin-2-one derivatives as prmt5 inhibitors | |
| JP2014520898A5 (https=) | ||
| JP2019535672A5 (https=) | ||
| RU2015149680A (ru) | Агенты для подавления активности и/или снижения количества bcl-xl и/или bcl-w | |
| MX2019015580A (es) | Metodos para tratar la enfermedad de huntington. | |
| RU2018138828A (ru) | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами | |
| RU2013142448A (ru) | Новые сульфонаминохинолиновые антагонисты гепсидина | |
| AR105809A1 (es) | Compuestos para el tratamiento de trastornos médicos | |
| EA201690094A1 (ru) | Ингибиторы syk | |
| PE20141296A1 (es) | Composiciones y metodos para tratar el virus de la hepatitis c | |
| HRP20211303T1 (hr) | Pripravci koji sadrže silimarin i sulfoalkil eter ciklodekstrin i postupci korištenja istih | |
| EA201171489A1 (ru) | Аминопиримидиновые противораковые соединения | |
| JP2011502174A5 (https=) | ||
| PE20160550A1 (es) | Formulaciones de (s)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona | |
| JP2015522049A5 (https=) | ||
| JP2016513696A5 (https=) | ||
| CA3092300C (en) | Compound and composition for prevention, alleviation or treatment of fibrosis or non-alcoholic steatohepatitis | |
| RU2016151420A (ru) | Новое терапевтическое применение производных бензилиденгуанидина для лечения протеинопатий | |
| JP2014513141A5 (https=) | ||
| CL2025001760A1 (es) | Compuesto quimérico protac, método de preparación del mismo y uso del mismo | |
| RU2016133471A (ru) | Композиции и способы для лечения диабета и заболеваний печени | |
| JP2013506674A5 (https=) | ||
| MX2021015447A (es) | Métodos de tratamiento del cáncer dirigidos a tumores fríos. |